Tonix Pharmaceuticals, Inc.
Novel small-molecule and biologic therapeutics and vaccines for CNS disorders, immunological conditions, infectious diseases, and rare diseases
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Founded
- 2007
- Latest Form D
- $150K, Aug 2010
- Total capital
- $150K
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $150K
- 1 Form D · last Aug 2010
- 194 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 15 pending · first 2016
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Seth LedermanResearcherExecutive Officer, Director, PromoterLinked by 1 patent
- Donald LandryDirectorNamed in SEC Form D filings
- Patrick GraceDirectorNamed in SEC Form D filings
- Stuart DavidsonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 16- PendingCyclobenzaprine For Treatment Or Prevention Of Sexual Dysfunction Associated With Mental Health Conditions In Female PatientsUSPTOApplication 18698483
- PendingRandomization Honoring Methods To Assess The Significance Of Interventions On Outcomes In DisordersUSPTOApplication 17508182
- GrantedIsometheptene IsomerUSPTOUS 9,403,755
Show all 16 patent records
- Cyclobenzaprine For Treatment Or Prevention Of Sexual Dysfunction Associated With Mental Health Conditions In Female PatientsDec 19, 2024 · Application 18698483Pending
- Randomization Honoring Methods To Assess The Significance Of Interventions On Outcomes In DisordersApr 28, 2022 · Application 17508182Pending
- Isometheptene IsomerAug 2, 2016 · US 9,403,755Granted
- Randomization Honoring Methods To Assess The Significance Of Interventions On Outcomes In DisordersApplication PCTUS2021056213Pending
- Cyclobenzaprine Treatment For Sexual DysfunctionApplication 63252964Pending
- Radio-and Chemo-protective CompoundsApplication PCTUS2021031441Pending
- Eutectic Formulations Of Cyclobenzaprine Hydrochloride And Amitriptyline HydrochlorideApplication PCTUS2014029872Pending
- Compositions And Methods For Transmucosal AbsorptionApplication PCTUS2014029688Pending
- Isometheptene IsomerApplication PCTUS2014012142Pending
- Isometheptene Isomer CrystalsApplication 61926739Pending
- Compositions And Methods For Transmucosal AbsorptionApplication PCTUS2013046023Pending
- Methods And Compositions For Treating Depression Using CyclobenzaprineApplication PCTUS2012027926Pending
- Treatment For Cocaine AddictionApplication PCTUS2011001529Pending
- Methods And Compositions For Treating Symptoms Associated With Post-traumatic Stress Disorder Using CyclobenzaprineApplication PCTUS2010002979Pending
- An Improved Method Of Assessing Clinical Response In The Treatment Of Ptsd SymptomsApplication PCTUS2022015327Pending
- Method Of Assessing Clinical Response In The Treatment Of Ptsd SymptomsApplication 63297918Pending
Related companies, and why
- RQ BioSimilar federal contract value in Biotech · null in contracts
- ImmVue Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
- Cyana Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
- PharmassetX Inc.Similar federal contract value in Biotech · null in contracts
- J2 Bio-Pharma, LLCSimilar federal contract value in Biotech · null in contracts
- Mimerigen, Inc.Similar federal contract value in Biotech · null in contracts
Press
Tonix Pharmaceuticals Q2 Earnings Call HighlightsMarketBeat
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .